Literature DB >> 31675264

Comprehensive Analysis of the Kinetics of Radiation-Induced Lymphocyte Loss in Patients Treated with External Beam Radiation Therapy.

Susannah G Ellsworth1, Anirudh Yalamanchali1, Hong Zhang1, Stuart A Grossman2, Robert Hobbs3, Jian-Yue Jin4.   

Abstract

Radiation-induced lymphopenia (RIL) is associated with worse survival in patients with solid tumors, as well as lower response rates to checkpoint inhibitors. While single-fraction total-body irradiation is known to result in exponential decreases in the absolute lymphocyte count (ALC), the kinetics of lymphocyte loss after focal fractionated exposures have not previously been characterized. In the current study, lymphocyte loss kinetics was analyzed among patients undergoing focal fractionated radiotherapy for clinical indications. This registry-based study included 419 patients who received either total-body irradiation (TBI; n = 30), stereotactic body radiation therapy (SBRT; n = 73) or conventionally fractionated chemoradiation therapy (CFRT; n = 316). For each patient, serial ALCs were plotted against radiotherapy fraction number. The initial three weeks of treatment for CFRT patients and the entirety of treatment for SBRT and TBI patients were fit to exponential decay in the form ALC(x) = ae-bx, where ALC(x) is the ALC after x fractions. From those fits, fractional lymphocyte loss (FLL) was calculated as FLL = (1 - e-b) * 100, and multivariable regression was performed to identify significant correlates of FLL. Median linearized R2 when fitting the initial fractions was 0.98, 0.93 and 0.97 for patients receiving TBI, SBRT and CFRT, respectively. In CFRT patients, apparent ALC loss rate slowed after week 3. Fitting ALC loss over the entire CFRT course therefore required the addition of a constant term, "c". For TBI and SBRT patients, treatment ended during the pure exponential decay phase. Initial FLL varied significantly with treatment technique. Mean FLL was 35.5%, 24.3% and 10.77% for patients receiving TBI, SBRT and CFRT, respectively (P < 0.001). Significant correlates of FLL varied by site and included field size, dose per fraction, mean spleen dose, chemotherapy backbone and age. Finally, total percentage ALC loss during radiotherapy was highly correlated with FLL (P < 0.001). Lymphocyte depletion kinetics during the initial phase of fractionated radiotherapy are characterized by pure exponential decay. Initial FLL is strongly correlated with radiotherapy planning parameters and total percentage ALC loss. The two groups with the highest FLL received no concurrent chemotherapy, suggesting that ALC loss can be a consequence of radiotherapy alone. This work may assist in selecting patients for adaptive radiotherapy approaches to mitigate RIL risk.

Entities:  

Mesh:

Year:  2019        PMID: 31675264     DOI: 10.1667/RR15367.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  8 in total

1.  A dynamic blood flow model to compute absorbed dose to circulating blood and lymphocytes in liver external beam radiotherapy.

Authors:  Shu Xing; Jungwook Shin; Jennifer Pursley; Camilo M Correa-Alfonso; Nicolas Depauw; Sean Domal; Julia Withrow; Wesley Bolch; Clemens Grassberger; Harald Paganetti
Journal:  Phys Med Biol       Date:  2022-02-15       Impact factor: 3.609

2.  HEDOS-a computational tool to assess radiation dose to circulating blood cells during external beam radiotherapy based on whole-body blood flow simulations.

Authors:  Jungwook Shin; Shu Xing; Lucas McCullum; Abdelkhalek Hammi; Jennifer Pursley; Camilo A Correa; Julia Withrow; Sean Domal; Wesley Bolch; Harald Paganetti; Clemens Grassberger
Journal:  Phys Med Biol       Date:  2021-08-03       Impact factor: 4.174

3.  Patient-Specific Lymphocyte Loss Kinetics as Biomarker of Spleen Dose in Patients Undergoing Radiation Therapy for Upper Abdominal Malignancies.

Authors:  Anirudh Yalamanchali; Hong Zhang; Ke Colin Huang; Radhe Mohan; Steven H Lin; Cong Zhu; Stuart A Grossman; Jian-Yue Jin; Susannah G Ellsworth
Journal:  Adv Radiat Oncol       Date:  2020-08-10

4.  Dynamics of Central Remyelination and Treatment Evolution in a Model of Multiple Sclerosis with Optic Coherence Tomography.

Authors:  Rocío Benítez-Fernández; Carolina Melero-Jerez; Carmen Gil; Enrique J de la Rosa; Ana Martínez; Fernando de Castro
Journal:  Int J Mol Sci       Date:  2021-02-28       Impact factor: 5.923

5.  Radiation-Induced Lymphopenia Risks of Photon Versus Proton Therapy for Esophageal Cancer Patients.

Authors:  Saba Ebrahimi; Gino Lim; Amy Liu; Steven H Lin; Susannah G Ellsworth; Clemens Grassberger; Radhe Mohan; Wenhua Cao
Journal:  Int J Part Ther       Date:  2021-04-07

6.  Prognostic value of absolute lymphocyte count in patients with advanced esophageal cancer treated with immunotherapy: a retrospective analysis.

Authors:  Qi Zhao; Yanping Bi; Jiao Xue; Yandong Liu; Jiaxing Zhu; Songbing Qin
Journal:  Ann Transl Med       Date:  2022-07

7.  Lymphocyte Depletion Rate as a Biomarker of Radiation Dose to Circulating Lymphocytes During Fractionated Partial-Body Radiation Therapy.

Authors:  Susannah G Ellsworth; Anirudh Yalamanchali; Tim Lautenschlaeger; Stuart A Grossman; Clemens Grassberger; Steven H Lin; Radhe Mohan
Journal:  Adv Radiat Oncol       Date:  2022-04-08

8.  Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC.

Authors:  Wang Jing; Ting Xu; Lirong Wu; Pablo B Lopez; Clemens Grassberger; Susannah G Ellsworth; Radhe Mohan; Brian P Hobbs; George R Blumenschein; Janet Tu; Mehmet Altan; Percy Lee; Zhongxing Liao; Steven H Lin
Journal:  JTO Clin Res Rep       Date:  2022-08-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.